Institution record
El Dorado
- Source score
- 5.0
- Warnings
- 0
- Comments
- 0
Licence records
Licences within our coverage (institutions licensed across asia-pacific and the middle east) are listed first. Check each one on the regulator's own register.
| Regulator | Licence no. | Status | Licensed entity | Date | |
|---|---|---|---|---|---|
Comisión Nacional de Valores | 30718568885 | Regulated | EL DORADO LABS SRL | — |
Peer regulatory & risk comparison
Side-by-side supervisory and risk benchmark comparing El Dorado against peer institutions in our institutions licensed across asia-pacific and the middle east dataset.
| Institution | Primary regulators | Regulated / total | Risk classification | Source score | Warnings |
|---|---|---|---|---|---|
| El Dorado (this record) | CNV | 1 / 1 | Risk level not supplied | 5.0 | 0 |
CRSFC | 2 / 2 | Risk level not supplied | 5.0 | 0 | |
FSA | 1 / 1 | Risk level not supplied | 7.0 | 0 | |
SFC | 1 / 1 | Risk level not supplied | 7.0 | 0 | |
FSA | 1 / 1 | Risk level not supplied | 7.0 | 0 | |
FSA | 1 / 1 | Risk level not supplied | 7.0 | 0 |
El Dorado: institutional due diligence FAQ
Key supervisory, licensing, and counterparty verification questions generated from the dataset.
What is El Dorado's regulatory licence status and supervisory authorisation?
In our imported dataset, El Dorado (legal entity reference: El Dorado) holds 1 recorded licence entry, of which 1 carries a "regulated" status and 1 are marked regulated or registered: CNV (Comisión Nacional de Valores) — licence 30718568885, status: regulated. Institutional due diligence requires verifying that the exact legal entity on your counterparty agreement matches the licensed entity name and registration number on the official CNV public register.
Which of El Dorado's jurisdictions and licences fall within this site's regulatory coverage?
El Dorado is tracked under our institutions licensed across asia-pacific and the middle east coverage scope based on its institutional service profile (multi-asset financial services) rather than a domestic focus licence. Its 1 recorded licence (CNV) should be evaluated for cross-border passporting and local solicitation rules.
What is El Dorado's institutional risk classification, enforcement exposure, and score profile?
El Dorado carries a "risk level not supplied" classification in the source dataset, alongside composite 5-dimension ratings out of 10 (overall: 5.0, risk & licensing: 5.0, brand: 5.0, market influence: 5.0, user reputation: 0.0). The record flags 0 regulatory warning or complaint counts. Because these figures reflect imported source fields rather than primary audit findings, compliance teams should review primary enforcement bulletins directly.
What operational due diligence steps apply to El Dorado's platforms, entity structure, and complaints?
Before allocating capital or executing trades with El Dorado, institutional and retail allocators should: (1) confirm the domain (not supplied in source) against regulator-approved domains to guard against clone firms; (2) verify whether any of the 0 recorded warning/complaint entries or 0 user comments involve withdrawal restrictions or scope violations; and (3) confirm the dispute-resolution ombudsman tied to CNV.
Related institutional research & regulatory analysis
Editorial briefings and compliance research from APAC Capital Brief relevant to El Dorado's supervisory scope.
Monetary Policy
Bank of Japan is expected to hold rates this week — but stay hawkish: CNBC survey
Bank of Japan is expected to hold rates this week — but stay hawkish: CNBC survey: All survey respondents said they expect the BOJ to set the stage for a rate hike in December or January, as inflation and wages continue to rise.
Monetary Policy
BOJ holds rates as underlying inflation aligns with 2% target for first time since 2013
BOJ holds rates as underlying inflation aligns with 2% target for first time since 2013: Institutional summary of the primary material (2%, 2013). Cross-reference official supervisory registers for live updates.
Market Insights
Nikkei Flat, Supported by Bank, Pharma Stocks
Nikkei Flat, Supported by Bank, Pharma Stocks: Japan’s Nikkei Stock Average was flat at 60451.02 as gains in bank and pharmaceutical shares offset losses in technology and machinery stocks.
Monetary Policy
Bank of Japan's Transactions with the Government (Oct.)
Bank of Japan's Transactions with the Government (Oct.): Institutional summary of the supplied primary disclosure. Cross-reference official supervisory registers for live updates.